Emerging Significance and Clinical Application of Liquid Biopsy in Early Diagnosis and Monitoring of Cancer

Precision medicine in the field of cancer management continues to evolve, and so do the challenges and demands regarding diagnosis, prognosis, and prediction of treatment resistance.1 The discovery of molecular agents that can target specific genomic changes in metastatic cancer patients has revolutionized patient care.2 The tumor heterogeneity remains a daunting obstacle for clinicians who need to optimize therapy regimens based on an individual's cancer genome.3 Tissue biopsies, which still currently represent the gold standard of tumor diagnosis, unfortunately only reflect a single point in time of a single site of the tumor. Such a sampling method is, thus, inadequate for the comprehensive characterization of a patient's tumor, as it has been demonstrated that various areas within the primary tumor or metastases can in fact harbor different genomic profiles.4 Furthermore, the procedure is invasive and causes discomfort to the patients when the clinicians opt for a repeat biopsy. Liquid biopsy is an innovative, minimally invasive technique that has gained significant attention in recent years for its potential in cancer diagnosis, prognosis, and treatment monitoring.5 Unlike traditional tissue biopsies, which require surgical procedures to obtain tumor samples, liquid biopsies analyze circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, and other biomarkers in body fluids such as blood, urine, or saliva.6 Thus, the utility of liquid biopsies provides deeper insights into tumor biology and improves patient care. Emerging Significance Liquid biopsies are less invasive compared to tissue biopsies, reducing patient discomfort and the risks associated with surgical procedures. Liquid biopsies can detect cancer-related mutations and alterations in cfDNA and CTCs even at early stages, potentially before symptoms appear.4-6 This enables earlier intervention and a better prognosis. Liquid biopsies allow for continuous monitoring of tumor dynamics and treatment response. This is crucial for adjusting therapeutic strategies promptly based on the molecular changes in the tumor. Liquid biopsies also provide a more comprehensive overview of tumor heterogeneity since they capture genetic information from multiple tumor sites and metastases, which might be missed in a single-site tissue biopsy.6 The procedure is associated with minimal risk, making it suitable for repeated sampling. This is particularly beneficial for tracking disease progression and resistance to therapy over time. Benefits of Liquid Biopsy in Early Diagnosis and Monitoring of Cancer Liquid biopsy has emerged as a transformative tool in the early diagnosis and monitoring of cancer, leveraging its noninvasive nature and ability to capture comprehensive tumor profiles from body fluids.7 Liquid biopsies help detect cfDNA with cancer-specific mutations and methylation patterns even at the early stages of the disease. Technologies such as next-generation sequencing and digital polymerase chain reaction are used to identify these alterations with high sensitivity. The presence of CTCs in the bloodstream can signal the existence of an early-stage tumor.5-7 Advances in microfluidics and immunoaffinity capture techniques have improved the ability to isolate and characterize CTCs. Liquid biopsies can be used to screen individuals at high risk of cancer, such as those with a family history or genetic predispositions (e.g., BRCA1/2 mutations for breast cancer). This proactive approach can lead to earlier detection and intervention.7 For patients presenting with nonspecific symptoms, liquid biopsies can help in the early diagnosis by identifying tumor-associated genetic and epigenetic changes, reducing the need for more invasive diagnostic procedures initially. By analyzing cfDNA and CTCs at multiple time points, liquid biopsies provide real-time information on how a tumor is responding to treatment. This can help in making timely decisions about continuing, changing, or stopping a therapy based on molecular changes.8 This is crucial for assessing the risk of relapse and deciding on additional therapeutic strategies. Tumors often develop resistance to treatments. Liquid biopsies can identify new genetic mutations or alterations that confer resistance, allowing for the adjustment of treatment regimens. Continuous monitoring of cfDNA levels and genetic alterations can help track the progression of the disease over time.5-7 These longitudinal data are valuable for understanding tumor evolution and adapting treatment plans accordingly. Quantitative analysis of CTCs and cfDNA can serve as prognostic indicators. Higher levels of these biomarkers are often associated with poorer outcomes, guiding the intensity and type of treatment required. The utility of liquid biopsy will reduce the need for surgical biopsies, leading to lower patient risk and discomfort.8 Liquid biopsy allows for regular and repeated sampling to monitor disease progression and treatment response. Liquid biopsy captures a wide range of genetic alterations from different tumor sites providing a more complete picture of tumor heterogeneity, it also provides quicker results compared to traditional biopsy, aiding in timely clinical decision- making.9 Clinical Applications Liquid biopsies are being developed for the early detection of cancers such as lung, breast, colorectal, and prostate cancers. Tests like those analyzing cfDNA fragments can identify cancer-specific mutations and methylation patterns. They help in identifying actionable genetic mutations and alterations, guiding the selection of targeted therapies and personalized treatment plans.7,8 For example, identifying epidermal growth factor receptor (EGFR) mutations in lung cancer can inform the use of tyrosine kinase inhibitors. Liquid biopsies can track changes in tumor burden and detect minimal residual disease. By measuring levels of specific biomarkers, clinicians can assess the effectiveness of treatment and make adjustments as necessary.8 Liquid biopsies enhance the identification of genetic mutations and alterations that confer resistance to ongoing therapies, allowing for the timely switch to alternative treatments. For instance, secondary mutations in the EGFR gene can indicate resistance to first-line EGFR inhibitors. Biomarkers detected through liquid biopsies can provide prognostic information, helping to predict disease progression and patient outcomes.2,3 For example, the presence and quantity of CTCs can correlate with metastatic potential and overall survival. Liquid biopsy helps the clinician to make appropriate clinical decisions and decide the extent and timing of surgical interventions by providing information on tumor burden and metastatic spread. Challenges, Consideration, and Future Directions Liquid biopsy represents a significant advancement in the field of oncology, offering a less invasive, more comprehensive, and dynamic method for cancer detection and management. As research and technology continue to evolve, liquid biopsies are expected to play an increasingly central role in precision medicine, transforming cancer care, and improving patient outcomes.9 Despite its potential, liquid biopsy faces several challenges. Ensuring high accuracy in detecting low-abundance tumor DNA amid a high background of normal DNA and high sensitivity and specificity is critical, as low concentrations of tumor-derived materials in body fluids can make detection difficult.9,10 Developing standardized protocols for sample collection, processing, and analysis is necessary to ensure reproducibility and reliability across different clinical settings. Extensive clinical trials are necessary to validate the efficacy and reliability of liquid biopsies in various cancer types and stages.10 Comprehensive clinical trials and regulatory approvals are required to validate the clinical utility and cost-effectiveness of liquid biopsy tests. Educating health-care providers and integrating liquid biopsy into existing clinical workflows will be essential for widespread adoption. Its ability to provide real-time, comprehensive, and minimally invasive insights into tumor biology makes it a powerful tool in the fight against cancer.11 As technologies advance and clinical validations continue, liquid biopsies are expected to become an integral part of personalized cancer care, improving early detection, guiding treatment decisions, and ultimately enhancing patient outcomes. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.